Kodiak Sciences reports data from study of KSI-101 in patients with MESI

Kodiak Sciences (KOD) announced follow-up data from the APEX study of KSI-101 in patients with MESI. MESI is a heterogenous group of serious vision threatening retinal diseases that clinically present with macular edema, or retinal fluid, and visual impairment, caused by a common pathophysiology of inflammation and blood retinal barrier disruption. Existing therapies remain limited by side effects and tolerability, underscoring the need for safer and more effective treatment options. KSI-101 is novel, potent and high strength antibody-based investigational therapy with a bispecific mechanism of action targeting both interleukin-6 and vascular endothelial growth factor. KSI-101 continued to be well tolerated with a favorable safety profile. Once completed, the results including Week 24 data will be presented by Sumit Sharma, retina and uveitis specialist at the Cleveland Clinic’s Cole Eye Institute, on February 7th, 2026, at the Angiogenesis, Exudation, and Degeneration 2026 Annual Meeting. The top two dose levels in APEX, KSI-101 5 mg and 10 mg have been advanced into the Phase 3 pivotal studies PEAK and PINNACLE. The PEAK and PINNACLE Studies are actively enrolling.